PBX1 and acute lymphoblastic leukemia: Patients with t(1;19) pre-B ALL generating the oncogenic fusion protein E2A-PBX1 were once considered to have poor prognosis and high risk of central nervous system relapse, but intensification of chemotherapy has improved outcome, although with increased risks of long-term toxicities [27].